FOLFOX Therapy Induces Feedback Upregulation of CD44v6 through YB-1 to Maintain Stemness in Colon Initiating Cells

FOLFOX Therapy Induces Feedback Upregulation of CD44v6 through YB-1 to Maintain Stemness in Colon Initiating Cells

Cancer initiating cells (CICs) drive tumor formation and drug-resistance, but how they develop drug-resistance characteristics is not well understood. In this study, we demonstrate that chemotherapeutic agent FOLFOX, commonly used for drug-resistant/metastatic colorectal cancer (CRC) treatment, indu...

Full description

Bibliographic Details
Main Authors:	Shibnath Ghatak, Vincent C. Hascall, Roger R. Markwald, Suniti Misra
Format:	Article
Language:	English
Published:	MDPI AG 2021-01-01
Series:	International Journal of Molecular Sciences
Subjects:	CD44v6 YB-1 MDR1 CIC stemness genes CD44v6 CRISPR/Cas9 knockout
Online Access:	https://www.mdpi.com/1422-0067/22/2/753

Similar Items

Chemotherapy induces feedback up-regulation of CD44v6 in colorectal cancer initiating cells through β-catenin/MDR1 signaling to sustain chemoresistance
by: Shibnath Ghatak, et al.
Published: (2022-10-01)

Interplay Between Chemotherapy-Activated Cancer Associated Fibroblasts and Cancer Initiating Cells Expressing CD44v6 Promotes Colon Cancer Resistance
by: Shibnath Ghatak, et al.
Published: (2022-08-01)

INTERACTIONS BETWEEN HYALURONAN AND ITS RECEPTORS (CD44, RHAMM) REGULATE THE ACTIVITIES OF INFLAMMATION AND CANCER
by: SUNITI eMISRA, et al.
Published: (2015-05-01)

CD44 Expression Profile Varies According to Maturational Subtypes and Molecular Profiles of Pediatric T-Cell Lymphoblastic Leukemia
by: Luísa Vieira Codeço Marques, et al.
Published: (2018-10-01)

Development of a Novel Anti-CD44 Variant 6 Monoclonal Antibody C<sub>44</sub>Mab-9 for Multiple Applications against Colorectal Carcinomas
by: Ryo Ejima, et al.
Published: (2023-02-01)

CD44 and CD44v6 are Correlated with Gastric Cancer Progression and Poor Patient Prognosis: Evidence from 42 Studies
by: Min Fang, et al.
Published: (2016-11-01)

Evaluation of CD44s, CD44v6, CXCR2, CXCL1, and IL-1β in Benign and Malignant Tumors of Salivary Glands
by: Fonthip Laohavisudhi, et al.
Published: (2022-05-01)

Clinicopathological significance of fascin and CD44v6 expression in endometrioid carcinoma
by: Gun Banu, et al.
Published: (2012-07-01)

A Novel Anti-CD44 Variant 9 Monoclonal Antibody C<sub>44</sub>Mab-1 Was Developed for Immunohistochemical Analyses against Colorectal Cancers
by: Mayuki Tawara, et al.
Published: (2023-04-01)

Prognostic Value of CD44 and Its Isoforms in Advanced Cancer: A Systematic Meta-Analysis With Trial Sequential Analysis
by: Susu Han, et al.
Published: (2019-02-01)

Interplay between Podoplanin, CD44s and CD44v in Squamous Carcinoma Cells
by: Lucía Montero-Montero, et al.
Published: (2020-09-01)

Predictive Value of CD44v6 and EGFR Expression in Neoadjuvant Chemotherapy Sensitivity of Stage Ⅱ-Ⅲ Cervical Cancer
by: MAO Wanli, et al.
Published: (2022-09-01)

A paclitaxel-hyaluronan conjugate (ONCOFID-P-B™) in patients with BCG-unresponsive carcinoma in situ of the bladder: a dynamic assessment of the tumor microenvironment
by: Anna Tosi, et al.
Published: (2024-04-01)

The Role of CD44 in Disease Pathophysiology And Targeted Treatment
by: Andre R. Jordan, et al.
Published: (2015-04-01)

The clinical significance of CD44v6 in malignant and benign primary bone tumors
by: Ameinh Hosseini, et al.
Published: (2023-07-01)

The v8-10 variant isoform of CD44 is selectively expressed in the normal human colonic stem cell niche and frequently is overexpressed in colon carcinomas during tumor development
by: Bruce M. Boman, et al.
Published: (2023-12-01)

Characteristics of CD44 alternative splice pattern in the course of human colorectal adenocarcinoma progression
by: Bánky Balázs, et al.
Published: (2012-11-01)

Next Generation CD44v6-Specific CAR-NK Cells Effective against Triple Negative Breast Cancer
by: Martin J. Raftery, et al.
Published: (2023-05-01)

Establishment of a Novel Anti-CD44 Variant 10 Monoclonal Antibody C<sub>44</sub>Mab-18 for Immunohistochemical Analysis against Oral Squamous Cell Carcinomas
by: Kenichiro Ishikawa, et al.
Published: (2023-06-01)

CD44v6-O-MWNTS-Loaded Gemcitabine and CXCR4 siRNA Improves the Anti-tumor Effectiveness of Ovarian Cancer
by: Wen Yin, et al.
Published: (2021-07-01)

Expression analysis of CD44 isoforms S and V3, in patients with esophageal squamous cell carcinoma
by: Atena Mansouri, et al.
Published: (2015-04-01)

High Expression of Osteopontin and CD44v6 in Odontogenic Keratocysts
by: Yi-Ping Wang, et al.
Published: (2009-04-01)

CD44v6 as innovative sarcoma target for CAR-redirected CIK cells
by: V. Leuci, et al.
Published: (2018-05-01)

1,2,3,4,6-Penta-O-galloyl-β-D-glucose Inhibits CD44v3, a cancer stem cell marker, by regulating its transcription factor, in human pancreatic cancer cell line
by: Eun-Young Kim, et al.
Published: (2022-11-01)

CD44 promotes hepatocellular carcinoma progression via upregulation of YAP
by: Jun Zhang, et al.
Published: (2021-11-01)

Correlation of CD44v6 and type IV collagen immunohistochemical expression in borderline and malignant surface epithelial tumors
by: Mohanad M. Abdul Ghany, et al.
Published: (2016-12-01)

Obesogenic and diabetic effects of CD44 in mice are sexually dimorphic and dependent on genetic background
by: Melissa VerHague, et al.
Published: (2022-04-01)

Expression of Bmi-1, P16, and CD44v6 in Uterine Cervical Carcinoma and Its Clinical Signifcance
by: Mei-ying Weng, et al.
Published: (2012-03-01)

Correlation of Soluble CD44 Expression in Saliva and CD44 Protein in Oral Leukoplakia Tissues
by: Ingrīda Čēma, et al.
Published: (2021-11-01)

Engineering Modular Half-Antibody Conjugated Nanoparticles for Targeting CD44v6-Expressing Cancer Cells
by: Bianca N. Lourenço, et al.
Published: (2021-01-01)

CD44 Contributes to the Regulation of MDR1 Protein and Doxorubicin Chemoresistance in Osteosarcoma
by: Monserrat Gerardo-Ramírez, et al.
Published: (2022-08-01)

Podoplanin Expression Independently and Jointly with Oral Epithelial Dysplasia Grade Acts as a Potential Biomarker of Malignant Transformation in Oral Leukoplakia
by: Luís Monteiro, et al.
Published: (2022-04-01)

RNA-binding proteins regulating the CD44 alternative splicing
by: Diana Maltseva, et al.
Published: (2023-12-01)

High Levels of Serum IgG for Opisthorchis viverrini and CD44 Expression Predict Worse Prognosis for Cholangiocarcinoma Patients after Curative Resection
by: Titapun A, et al.
Published: (2021-06-01)

Development of a Novel Anti-CD44 Variant 4 Monoclonal Antibody C<sub>44</sub>Mab-108 for Immunohistochemistry
by: Hiroyuki Suzuki, et al.
Published: (2023-02-01)

A Novel Anti-CD44 Variant 3 Monoclonal Antibody C<sub>44</sub>Mab-6 Was Established for Multiple Applications
by: Hiroyuki Suzuki, et al.
Published: (2023-05-01)

CD44 In Sarcomas: A Comprehensive Review and Future Perspectives
by: Enrique Fernández-Tabanera, et al.
Published: (2022-06-01)

Development of a Novel Anti-CD44 Variant 5 Monoclonal Antibody C<sub>44</sub>Mab-3 for Multiple Applications against Pancreatic Carcinomas
by: Yuma Kudo, et al.
Published: (2023-04-01)

CD44V3, an Alternatively Spliced Form of CD44, Promotes Pancreatic Cancer Progression
by: Hanzhang Zhu, et al.
Published: (2022-10-01)

CD44v6 expression in human skin keratinocytes as a possible mechanism for carcinogenesis associated with chronic arsenic exposure
by: S. Huang, et al.
Published: (2013-01-01)